OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
S. Vincent Rajkumar
American Journal of Hematology (2022) Vol. 97, Iss. 8, pp. 1086-1107
Open Access | Times Cited: 548
S. Vincent Rajkumar
American Journal of Hematology (2022) Vol. 97, Iss. 8, pp. 1086-1107
Open Access | Times Cited: 548
Showing 26-50 of 548 citing articles:
Liquid biopsy in hematological malignancies: current and future applications
Donatella Talotta, Mohammad Almasri, Chiara Cosentino, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 15
Donatella Talotta, Mohammad Almasri, Chiara Cosentino, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 15
Bispecific antibody therapies
Luiz Henrique de Assis, Daniel El Fassi, Martin Hutchings
Hematology (2023) Vol. 2023, Iss. 1, pp. 216-222
Closed Access | Times Cited: 15
Luiz Henrique de Assis, Daniel El Fassi, Martin Hutchings
Hematology (2023) Vol. 2023, Iss. 1, pp. 216-222
Closed Access | Times Cited: 15
Perspectives on the Treatment of Multiple Myeloma
Abdul Rafae, Frits van Rhee, Samer Al Hadidi
The Oncologist (2023) Vol. 29, Iss. 3, pp. 200-212
Open Access | Times Cited: 14
Abdul Rafae, Frits van Rhee, Samer Al Hadidi
The Oncologist (2023) Vol. 29, Iss. 3, pp. 200-212
Open Access | Times Cited: 14
Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes
Mégane Tanguay, Christophe Dagenais, Richard LeBlanc, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5214-5226
Open Access | Times Cited: 13
Mégane Tanguay, Christophe Dagenais, Richard LeBlanc, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5214-5226
Open Access | Times Cited: 13
Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
Alejandro Medina, María Eugenia Sarasquete, Cristina Jiménez, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3687-3687
Open Access | Times Cited: 13
Alejandro Medina, María Eugenia Sarasquete, Cristina Jiménez, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3687-3687
Open Access | Times Cited: 13
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells
Dorien Clarisse, Stefan Prekovic, Philip Vlummens, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 9
Open Access | Times Cited: 13
Dorien Clarisse, Stefan Prekovic, Philip Vlummens, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 9
Open Access | Times Cited: 13
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
Yan Cheng, Fumou Sun, Daisy Alapat, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101214-101214
Open Access | Times Cited: 13
Yan Cheng, Fumou Sun, Daisy Alapat, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101214-101214
Open Access | Times Cited: 13
Selinexor in multiple myeloma
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 4, pp. 421-434
Closed Access | Times Cited: 5
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 4, pp. 421-434
Closed Access | Times Cited: 5
Low TYROBP expression predicts poor prognosis in multiple myeloma
Hong Luo, Chengyun Pan, Li Wang, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Hong Luo, Chengyun Pan, Li Wang, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
A comprehensive approach to evaluate genetic abnormalities in multiple myeloma using optical genome mapping
Ying Zou, Melanie Klausner, Jen Ghabrial, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Ying Zou, Melanie Klausner, Jen Ghabrial, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 10, pp. e329-e335
Closed Access | Times Cited: 5
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 10, pp. e329-e335
Closed Access | Times Cited: 5
Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence
Monique Hartley-Brown, Katja Weisel, Jacopo Bitetti, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 780-797
Open Access | Times Cited: 5
Monique Hartley-Brown, Katja Weisel, Jacopo Bitetti, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 780-797
Open Access | Times Cited: 5
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐BCMA CAR T‐cell‐based therapy
Yuekun Qi, Hujun Li, Kunming Qi, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 12, pp. 2286-2295
Open Access | Times Cited: 5
Yuekun Qi, Hujun Li, Kunming Qi, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 12, pp. 2286-2295
Open Access | Times Cited: 5
Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carfilzomib and anti-CD38 monoclonal antibodies
Luciano J. Costa, Francesca Gay, Ola Landgren, et al.
Annals of Hematology (2025)
Open Access
Luciano J. Costa, Francesca Gay, Ola Landgren, et al.
Annals of Hematology (2025)
Open Access
Engineered T cells secreting αB7-H3-αCD3 bispecific engagers for enhanced anti-tumor activity against B7-H3 positive multiple myeloma: a novel therapeutic approach
Punchita Rujirachaivej, Teerapong Siriboonpiputtana, Kornkan Choomee, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Punchita Rujirachaivej, Teerapong Siriboonpiputtana, Kornkan Choomee, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes
Anuja Anil Mandavkar, Suraj Sai Nikhil Padakanti, Srajan Gupta, et al.
Human Antibodies (2025)
Closed Access
Anuja Anil Mandavkar, Suraj Sai Nikhil Padakanti, Srajan Gupta, et al.
Human Antibodies (2025)
Closed Access
A Markov model for estimating the cost-effectiveness of immunotherapy for newly diagnosed multiple myeloma patients
Massimo Bilancia, Antonio Giovanni Solimando, Fabio Manca, et al.
Computational Statistics & Data Analysis (2025), pp. 108130-108130
Closed Access
Massimo Bilancia, Antonio Giovanni Solimando, Fabio Manca, et al.
Computational Statistics & Data Analysis (2025), pp. 108130-108130
Closed Access
Extramedullary Disease of the Breast in Multiple Myeloma—An Uncommon Initial Presentation: A Case Report and Review of Literature
Prashanth Venkataraman, N.K. Mehra, Shirley Sundersingh, et al.
Indian Journal of Medical and Paediatric Oncology (2025)
Open Access
Prashanth Venkataraman, N.K. Mehra, Shirley Sundersingh, et al.
Indian Journal of Medical and Paediatric Oncology (2025)
Open Access
Evaluation of plasma cell sorting methods in multiple myeloma patients: flow cytometry versus magnetic beads
Yu Jeong Choi, Jaeguk Choi, Y. Kang, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Yu Jeong Choi, Jaeguk Choi, Y. Kang, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Predicting the Progression from Asymptomatic to Symptomatic Multiple Myeloma and Stage Classification Using Gene Expression Data
Nestoras Karathanasis, George M. Spyrou
Cancers (2025) Vol. 17, Iss. 2, pp. 332-332
Open Access
Nestoras Karathanasis, George M. Spyrou
Cancers (2025) Vol. 17, Iss. 2, pp. 332-332
Open Access
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
Sonia Morè, Irene Federici, Alessandra Bossi, et al.
HemaSphere (2025) Vol. 9, Iss. 1
Open Access
Sonia Morè, Irene Federici, Alessandra Bossi, et al.
HemaSphere (2025) Vol. 9, Iss. 1
Open Access
The Role of Ferritin and Folate in Determining Stem Cell Collection for Autologous Stem Cell Transplant in Multiple Myeloma
Charles Weeks, Mohammad Mian, Michael Stokes, et al.
Hematology Reports (2025) Vol. 17, Iss. 1, pp. 5-5
Open Access
Charles Weeks, Mohammad Mian, Michael Stokes, et al.
Hematology Reports (2025) Vol. 17, Iss. 1, pp. 5-5
Open Access
Detection of early relapse in multiple myeloma patients
Tereza Růžičková, Monika Vlachová, Lukáš Pečínka, et al.
Cell Division (2025) Vol. 20, Iss. 1
Open Access
Tereza Růžičková, Monika Vlachová, Lukáš Pečínka, et al.
Cell Division (2025) Vol. 20, Iss. 1
Open Access
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Susanna Kim, Adam ElSayed, Jonathan E. Moore, et al.
Targeted Oncology (2025)
Closed Access
Susanna Kim, Adam ElSayed, Jonathan E. Moore, et al.
Targeted Oncology (2025)
Closed Access
Targeting ABCD1-ACOX1-MET/IGF1R axis suppresses multiple myeloma
Zhannan Han, Zhibo Yan, Zhehan Ma, et al.
Leukemia (2025)
Closed Access
Zhannan Han, Zhibo Yan, Zhehan Ma, et al.
Leukemia (2025)
Closed Access
